Triplett DA, Antiphospholipid-protein antibodies: laboratory detection and clinical relevance . Thromb Res1995; 78: 1-31.
2.
McNeil HP, Simpson RJ, Chesterman CN, Krilis SAAntiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β2 Glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA1990; 4120-4124.
3.
Bevers EM et al. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only but to a complex of lipid bound prothrombin. Thromb Haemost1991; 66: 629-632.
4.
Matsuda J. et al. Anti-annexin antibody in the sera of patients with habitual fetal loss or pre-eclampsia. Thromb Res1994 ; 75: 105-106.
5.
Oosting JD et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S. An explanation for their pathogenic mechanism. Blood1993; 81: 2618-2625.
6.
Sugi T., McIntyre JA. Auto-antibodies to phosphatidylethanolamine (PE) recognise a kinogen-PE complex. Blood1995; 86: 3083-3089.
Ginsberg KS et al. Anticardiolipin antibodies and the risk for ischaemic stroke and venous thrombosis. Annals of Internal Medicine1992; 117: 997-1002.
9.
Taylor LM et al. Antiphospholipid antibodies in vascular surgery patients. Ann Surg1994; 220: 544-551.
10.
Morton KE et al. Coronary artery bypass graft failure - an autoimmune phenomenon ? Lancet1986; 2: 1353-1357.
11.
Ginsberg JS et al. Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state. Blood1993; 81: 2958-2963.
12.
Khamashta MA et al. The management of thrombosis in the antiphospholipid antibody syndrome. New Eng J Med1995; 332(15): 993-997.
13.
Denheizer M. et al. Is hyperhomocystinaemia a risk factor for recurrent venous thrombosis?Lancet1995 ; 345: 882-885.
14.
Naworth PD, Handley DA, Esmon CT, Slern D.Interleukin I induces endothelial procoagulant while suppressing cell surface anticoagulant activity. Proc Natl Acad Sci USA1986; 83: 3460.
15.
Comp PC et al. Acquired protein S deficiency occurs in pregnancy, the nephrotic syndrome and systemic lupus erythematosus. Blood1985; 66: 348.
16.
Dahlback B.Inherited thrombophilia resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood1995; 85: 607-614.
17.
Esmon CTThe regulation of natural anticoagulant pathways. Science1987; 235: 1348-1352.
18.
Griffin JH et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest1981; 68: 1370-1373.
19.
Mitchell CA et al. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. New Engl J Med1987; 317: 1638-1642.
20.
Odegaard B. , Mann KG: Proteolysis of factor Va by factor Xa and activated protein C. J Biol Chem1987; 262: 11233.
21.
Zoller B., Dahlback B.: Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet1994 ; 343: 1536.
22.
Heeb MJ, Kojima Y., Greengard JS, Griffin JHActivated protein C resistance molecular mechanisms based on studies using purified (GLN 506) Factor V. Blood1995 ; 85: 3405-3411.
23.
Hellgren M. , Svenson PJ, Dahlback B.: Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives . Am J Obstet Gyn1995; 173: 210-213.
24.
Ridker PM et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. New Engl J Med1995; 332: 912-917.
